News

Biohaven Pharmaceutical has dosed the first amyotrophic lateral sclerosis (ALS) patient with its sublingual formulation of riluzole, BHV-0223, in a pivotal Phase 2/3 trial. The trial aims to demonstrate that BHV-0223’s effects are at least equivalent to Rilutek, an approved tablet formulation of riluzole. The trial initiation was supported by…

Option Care Enterprises, a Chicago-based independent provider of home and alternate treatment site infusion services, has partnered with the ALS Association to offer Radicava (edaravone) treatment from the comfort of their homes. To date, more than 100 amyotrophic lateral sclerosis (ALS) patients are already receiving Radicava — the first…

The U.S. Food and Drug Administration (FDA) has given the green light to Biohaven Pharmaceuticals to advance sublingual BHV-0223, which regulates glutamate communication between neurons, into clinical trials for amyotrophic lateral sclerosis (ALS) patients. The FDA’s  permission to go ahead with the study followed Biohaven’s submission of an investigational new drug…

Repeated severe trauma to the body or mild injuries to the head — especially at midlife — raise a person’s risk of ALS, a European case-control study from the EURALS consortium shows. The new research, “Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from…

Children’s National Health System no longer treats just kids. Its Rare Disease Institute, launched in April 2017, has partnered with the National Organization for Rare Disorders (NORD) to become the first of many U.S. “centers of excellence” to look after patients with rare diseases, regardless of age. The effort…

In some neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), nerve cells fold their proteins incorrectly, leading to cell death. Using plants, researchers discovered that when defective proteins accumulate in chloroplasts – a plant’s cellular compartment where photosynthesis occurs – it generates a distress signal that produces reparative proteins to…

A nervous system mechanism that helps control heart rate and blood pressure goes into overdrive in patients with a type of ALS that eliminates mobility and sensation in some limbs, a study reports. The control mechanism is known as sympathetic vascular response — with vascular response referring to heart blood vessels.

BrainStorm Cell Therapeutics is expanding the patent portfolio that protects its NurOwn technology for the treatment of several diseases affecting the central nervous system. The latest U.S. patent claim includes Parkinson’s disease and ALS (amyotrophic lateral sclerosis). The announcement by BrainStorm follows a Notice of Allowance issued by…

​Researchers generated motor neurons from  amyotrophic lateral sclerosis (ALS) patients with a mutated gene found in familial forms of the disease. The study sheds new light on the disease mechanism. Transport of materials up and down the motors’ neuron length (axon) keeps nerve cell messages…

Relatives of patients with amyotrophic lateral sclerosis (ALS) have a higher likelihood of developing neuropsychiatric symptoms including schizophrenia, obsessive-compulsive disorder, autism, and alcoholism, research from Ireland shows. The study, “Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis,” was published…